“Learn how pharmaceutical manufacturers can achieve compliance with FDA cGMP regulations, ensuring safety, quality, and efficacy in drug production.”
The pharmaceutical industry is formally regulated to ensure the safety, efficacy, and quality of the relevant drugs on a national and international level. For instance, one of the most basic regulations is Title 21 Food and Drugs, Chapter I Food and Drug Administration (FDA) Subchapter C Drugs: General, part 211. Current Good Manufacturing Practice for Finished Pharmaceuticals. The final rule widely known as current Good Manufacturing Practice (cGMP) establishes requirements that apply to components, any drug product container and closure in which they are packaged, which are necessary to ensure appropriate control over quality. This article will examine some of the top requirements and how pharmaceutical companies can meet those.
The need for compliance:
Compliance with current Good Manufacturing Practices is of utmost importance to pharmaceutical manufacturers concerned about protecting public health and the integrity of their products. One of the best ways for companies to ensure that drugs are safe and pure and effective for consumption is by strictly following these standards. Failure to comply can have serious ramifications, including product recalls, regulatory actions, litigation and damage to the company’s name.
When components, drug product containers and closures are received, each lot must be appropriately sampled and tested (or examined) by the quality control unit to comply with cGMP. Sampling of each shipment should be performed, depending on statistical criteria, confidence levels and quality history of the supplier. Sufficient samples are collected for analysis and reserve from each container.
Sampling Procedures:
It is of utmost importance to follow the proper sampling procedures to minimize contamination and obtain accurate test results. When necessary, containers chosen for sampling should be cleaned if it may result in the introduction of contamination. Containers must be opened, sampled, and resealed in a way to prevent contamination of the container contents or contamination of other components; drug product containers; or closures. Use Appropriate Equipment whenever needed. Sterile equipment and aseptic sampling techniques should be employed to maintain aseptic conditions.
Testing:
Containers, Components, Drug product containers and Closures must be tested for compliance with written specifications for identity, purity, strength or quality as required. For all components, identity tests should be performed and refer to specific tests if available. In general, manufacturers might accept a certificate of analysis from component suppliers so long as they perform at least one identity test on each component and verify the reliability of that result into their own specification requirements.
Container and Closure Testing
Containers and closures should also be tested in accordance with suitable written specifications. Manufacturer can accept a certificate of testing from the supplier, but they are required to identify the containers and closures at least visually and periodically verify the reliability of test results by a supplier test.
Microscopic Examination and Contamination Control:
The type of component you manufacture may require microscopic examination as certain defects can only be seen using a microscope. You must also test for specified characteristics at least every lot of the components, drug product containers, or closures which are liable to contamination with filth, insect habitation and other extraneous substituents. Similarly, lots exhibiting potential for microbiological contamination must be tested microbiologically before utilization.
Approval and Rejection:
The samples are then evaluated and tested, and lots that meet the applicable written specifications for identity, strength, quality and purity can be approved and released for use. However, if any lot does not conform to these specifications, it must be rejected.
Conclusion: Ensuring Drug Safety and Quality through cGMP Compliance
cGMP Compliance has always been a necessity for pharmaceutical manufacturers to provide safe and quality products. Maintaining quality manufacturing practices is important for compliance with Title 21, Chapter I, Subchapter C, Part 211 of the FDA regulations. With the right sampling and testing practices, identity and content verification tests, contamination control levels, these companies can ensure compliance with FDA rules and quash both their quality concerns as well as public health concerns.
Reach out to BioBoston Consulting or check our website to find out how we can serve your organization.
